Articles related to PROSTATE CANCER

Prebiopsy prostate MRI use increased substantially across US hospitals between 2017 and 2026, reflecting broader uptake of guideline-supported imaging, although a substantial proportion of patients still undergo biopsy without MRI evaluation.

Prostate cancer screening continues to rely on individualized risk assessment, PSA monitoring, and shared decision-making, while advances in MRI imaging and biomarker testing may help refine biopsy decisions and reduce unnecessary invasive procedures.

National Cancer Database data suggest that approximately half of prostate cancer focal therapy use from 2010 to 2023 occurred outside current guideline-supported settings, highlighting persistent gaps between clinical practice and available evidence.

Artificial intelligence tools are increasingly being integrated into prostate cancer imaging, pathology, prognostication, and treatment planning. Although several platforms have demonstrated promising accuracy and workflow benefits, broad clinical adoption will require prospective validation, regulatory oversight, and careful implementation.

Researchers identified a metabolic pathway in which amino acid breakdown generates propionyl-CoA, sustaining cholesterol production and androgen signaling in prostate cancer models. The findings suggest a potential mechanism of hormone therapy resistance, though clinical relevance remains unproven.

A Veterans Health Administration analysis of 4,890 men with metastatic hormone-sensitive prostate cancer found that achieving a PSA level below 0.2 ng/mL within 9 months was associated with improved survival. The retrospective findings support a threshold previously identified in clinical trials.